NasdaqGS:BCRXBiotechs
BioCryst Pharmaceuticals (BCRX) Is Up 15.4% After First Profitable Year And HAE Portfolio Expansion - Has The Bull Case Changed?
In late February 2026, BioCryst Pharmaceuticals reported fourth-quarter 2025 revenue of US$406.56 million and net income of US$245.85 million, capping its first full year of profitability with US$874.84 million in revenue and US$263.86 million in net income.
The move into sustained profitability, underpinned by strong ORLADEYO performance and the Astria Therapeutics acquisition that broadened its hereditary angioedema portfolio, marks a step-change in BioCryst’s financial and competitive...